Rituximab-induced T cell depletion in patients with rheumatoid arthritis: Association with clinical response

Arthritis and Rheumatism

Volumn 65, Issue 11, 2013, Pages 2783-2790

  Melet J ^a   Mulleman, D ^a   Goupille, P ^a   Ribourtout, B ^a   Watier, H ^a   Thibault, G ^a  

^a UNIVERSITÉ DE TOURS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; METHYLPREDNISOLONE; RITUXIMAB;

ADULT; AGED; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; T CELL DEPLETION;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DRUG MONITORING; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; MIDDLE AGED;

EID: 84886790652     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.38107     Document Type: Article

References (28)

1. Gregersen PK, Silver J, Winchester RJ,. The shared epitope hypothesis: an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987; 30: 1205-13.
2. Choy EH, Connolly DJ, Rapson N, Jeal S, Brown JC, Kingsley GH, et al. Pharmacokinetic, pharmacodynamic and clinical effects of a humanized IgG1 anti-CD4 monoclonal antibody in the peripheral blood and synovial fluid of rheumatoid arthritis patients. Rheumatology (Oxford) 2000; 39: 1139-46.
3. Scheerens H, Su Z, Irving B, Townsend MJ, Zheng Y, Stefanich E, et al. MTRX1011A, a humanized anti-CD4 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled study incorporating pharmacodynamic biomarker assessments. Arthritis Res Ther 2011; 13: R177.
4. Kremer JM, Dougados M, Emery P, Durez P, Sibilia J, Shergy W, et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase IIb, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005; 52: 2263-71.
5. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al, for the REFLEX Trial Group. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006; 54: 2793-806.
6. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350: 2572-81.
7. Chan OT, Hannum LG, Haberman AM, Madaio MP, Shlomchik MJ,. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med 1999; 189: 1639-48.
8. Sfikakis PP, Boletis JN, Lionaki S, Vigklis V, Fragiadaki KG, Iniotaki A, et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum 2005; 52: 501-13.
9. Saadoun D, Rosenzwajg M, Landau D, Piette JC, Klatzmann D, Cacoub P,. Restoration of peripheral immune homeostasis after rituximab in mixed cryoglobulinemia vasculitis. Blood 2008; 111: 5334-41.
10. Couderc M, Mathieu S, Pereira B, Glace B, Soubrier M,. Predictive factors of rituximab response in rheumatoid arthritis: results from a French university hospital. Arthritis Care Res (Hoboken) 2013; 65: 648-52.
11. Isaacs JD, Cohen SB, Emery P, Tak PP, Wang J, Lei G, et al. Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis. Ann Rheum Dis 2013; 72: 329-36.
12. Clifford DB, Ances B, Costello C, Rosen-Schmidt S, Andersson M, Parks D, et al. Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol 2011; 68: 1156-64.
13. Fleischmann RM,. Progressive multifocal leukoencephalopathy following rituximab treatment in a patient with rheumatoid arthritis. Arthritis Rheum 2009; 60: 3225-8.
14. Teichmann LL, Woenckhaus M, Vogel C, Salzberger B, Scholmerich J, Fleck M,. Fatal Pneumocystis pneumonia following rituximab administration for rheumatoid arthritis. Rheumatology (Oxford) 2008; 47: 1256-7.
15. Vallet H, Houitte R, Azria A, Mariette X,. Cytomegalovirus colitis and hypo-IgG after rituximab therapy for rheumatoid arthritis. J Rheumatol 2011; 38: 965-6.
16. Van Vollenhoven RF, Emery P, Bingham CO III, Keystone EC, Fleischmann RM, Furst DE, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis 2013; 72: 1496-502.
17. Wingfield T, Jani M, Krutikov M, Mayer J, Uriel A, Marks J, et al. Cryptococcal meningitis in an HIV-negative patient with rheumatoid arthritis treated with rituximab. Rheumatology (Oxford) 2011; 50: 1725-7.
18. Pham T, Fautrel B, Gottenberg JE, Goupille P, Hachulla E, Masson C, et al. Rituximab (MabThera) therapy and safety management. Clinical tool guide. Joint Bone Spine 2008; 75 Suppl 1: S1-99.
19. Vital EM, Dass S, Rawstron AC, Buch MH, Goeb V, Henshaw K, et al. Management of nonresponse to rituximab in rheumatoid arthritis: predictors and outcome of re-treatment. Arthritis Rheum 2010; 62: 1273-9.
20. Roll P, Dorner T, Tony HP,. Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment. Arthritis Rheum 2008; 58: 1566-75.
21. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL,. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
22. Van Gestel AM, Prevoo ML, van't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL,. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996; 39: 34-40.
23. Feuchtenberger M, Muller S, Roll P, Waschbisch A, Schafer A, Kneitz C, et al. Frequency of regulatory T cells is not affected by transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Open Rheumatol J 2008; 2: 81-8.
24. Thurlings RM, Vos K, Wijbrandts CA, Zwinderman AH, Gerlag DM, Tak PP,. Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response. Ann Rheum Dis 2008; 67: 917-25.
25. Iwata S, Saito K, Tokunaga M, Yamaoka K, Nawata M, Yukawa S, et al. Phenotypic changes of lymphocytes in patients with systemic lupus erythematosus who are in longterm remission after B cell depletion therapy with rituximab. J Rheumatol 2011; 38: 633-41.
26. Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC,. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54: 613-20.
27. Yanaba K, Bouaziz JD, Matsushita T, Magro CM, St Clair EW, Tedder TF,. B-lymphocyte contributions to human autoimmune disease. Immunol Rev 2008; 223: 284-99.
28. Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H,. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58: 1-207.